Nutraceutix Inc. Acquires Global Rights to Newly Issued Pharmaceutical Patent From Temple University.Health/Medical Writers REDMOND, Wash.--(BW HealthWire)--Nov. 16, 2000 Nutraceutix Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: NUTX), has recently acquired the exclusive, worldwide rights to a newly issued patent (U.S. Patent No. 6,090,411) from Temple University School of Pharmacy, Philadelphia, for the development of controlled delivery, oral dosage forms of pharmaceuticals, Over-the-Counter (OTC) products, and dietary/health supplements (nutraceuticals). This is the second drug delivery patent developed in the laboratory of Dr. Reza Fassihi, Ph.D., that has been licensed to Nutraceutix Inc., a leading provider of new technologies to the pharmaceutical, OTC, and nutraceutical industries. This technology may be a milestone in delivery technology since it addresses many of the challenges common to delivery systems that are currently available. The new technology has been experimentally implemented into a range of established pharmaceuticals, such as nifedipine nifedipine /ni·fed·i·pine/ (ni-fed´i-pen) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension. , theophylline theophylline /the·oph·yl·line/ (the-of´i-lin) a xanthine derivative found in tea leaves and prepared synthetically; its salts and derivatives act as smooth muscle relaxants, central nervous system and cardiac muscle stimulants, and , propanolol, diltiazem, and verapamil verapamil /ve·rap·a·mil/ (ve-rap´ah-mil) a calcium channel blocker that dilates coronary arteries and decreases myocardial oxygen demand, used as the hydrochloride salt in the treatment of angina pectoris and of hypertension and the . According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. David T. Howard, president & chief executive officer of Nutraceutix Inc., "This new patent provides Nutraceutix with a clear technological advantage over first generation, controlled delivery systems. We will seek to partner with major pharmaceutical, OTC, and nutritional companies to co-develop products incorporating Nutraceutix' technology platforms." Management anticipates that it will be late in the year 2001 before any revenues may be realized from this new acquisition. Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry. In addition to patented ingredients like Calcium D-Glucarate, Nutraceutix provides patented and proprietary technologies like CDT CDT abbr. Central Daylight Time CDT Central Daylight Time CDT n abbr (US) (= Central Daylight Time) → hora de verano del centro; (BRIT (TM) Controlled Delivery Technology, MDT MDT abbr. Mountain Daylight Time MDT (in the US and Canada) Mountain Daylight Time MDT n abbr (US) (= mountain daylight time) → (TM) Molecular Dispersion Technology, S.E.T(TM) Self Emulsifying Technology and LiveBac(R) Probiotics Probiotics Bacteria that are beneficial to a person's health, either through protecting the body against pathogenic bacteria or assisting in recovery from an illness. Mentioned in: Colonic Irrigation, Dysentery, Gastroenteritis . Nutraceutix technologies provide distinctive supplements with tangible benefits for the consumer and competitive commercial advantages. For more information on Nutraceutix, please call 800/548-3222, or visit www.nutraceutix.com. Except for any historical information, the matters discussed in this press release contain forward-looking statements, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statement. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion